CD274 and neoplasm: PD-L1–expressing EVs have been proposed as predictive biomarkers to stratify patients for immune checkpoint inhibitor therapy, particularly in non-responders with low tumor cell PD-L1 expression but high EV-PD-L1 burden (59).